Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength

Innoviva, Inc. (NASDAQ:INVA) is one of the best small-cap value stocks to buy. On April 8, Cantor Fitzgerald reiterated an Overweight rating on Innoviva Inc. (NASDAQ:INVA) and a $32 price target. The research firm remains confident about the company’s prospects, owing to the stability of its recurring royalty business that generated about $250 million in 2025.

The research firm expects the royalty recurring business to provide significant stock protection. That’s in part because the company is increasingly investing to grow the royalty revenue base in the Specialty Therapeutics segment. The segment boasts $175 million in trailing-12-month revenue.

Innoviva also owns a large equity stake of about 70% in Armata Pharmaceuticals, which is also expected to drive long-term growth and differentiation. The company also remains well capitalized, with multiple value-accretive capital deployment opportunities across the current business, novel assets, and capital strategies.

Innoviva, Inc. (NASDAQ:INVA) is a diversified holding company that manages a portfolio of biopharmaceutical royalties and invests in, develops, and commercializes healthcare assets. Its core business focuses on royalties from respiratory products (RELVAR®/BREO® and ANORO® ELLIPTA®) partnered with GSK, alongside a specialized therapeutic platform, Innoviva Specialty Therapeutics, focused on critical care and infectious diseases.

While we acknowledge the risk and potential of INVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Most Oversold Canadian Stocks to Invest In and 10 Best Stocks to Buy in 2026 According to Billionaire George Soros.

Disclosure: None. Follow Insider Monkey on Google News.